Browse
Submit Data
Databases
API
Help

Dataset Information

0 Views

0 Connections

0 Citations

0 Reanalyses

0 Downloads

Omics score: 0

Genome-wide CRISPR Knockout Screen in LNCaP Cells Treated with Enzalutamide

ABSTRACT: Genome-wide CRISPR Knockout Screen in LNCaP Cells Treated with Enzalutamide

PROVIDER: PRJNA942353 | ENA |

REPOSITORIES: ENA

ACCESS DATA

Json Xml

Dataset's files

Source:

			Action	DRS
	SRR23753783.fastq.gz	Fastqsanger.gz
	SRR23753784.fastq.gz	Fastqsanger.gz
	SRR23753785.fastq.gz	Fastqsanger.gz
	SRR23753786.fastq.gz	Fastqsanger.gz
	SRR23753787.fastq.gz	Fastqsanger.gz

Items per page:

1 - 5 of 12

Similar Datasets

Genome-wide CRISPR Knockout Screen in LNCaP Cells Treated with Enzalutamide

Project description:To categorize gene loss events in enzalutamide-treated LNCaP cells, a genome-wide CRISPR knockout (KO) screen was performed. We quantified sgRNA abundance between initial and final timepoints in DMSO and enzalutamide treated cell populations

2024-09-30 | GSE226977 | GEO

RNA-Sequencing Analysis of LNCaP Wildtype (WT) and RB-p53 CRISPR-Cas9 Double Knockout (DKO) Cells Treated with Enzalutamide

Project description:To investigate differential gene expression between LNCaP wild type (WT) cells and cells deficient for RB and p53 in the presence of absence of enzalutamide To investigate differential gene expression between LNCaP wild type (WT) cells and cells deficient for RB and p53 (generated using CRISPR-Cas9) in the presence of absence of enzalutamide

2024-09-30 | GSE226978 | GEO

CRISPR screen in LNCaP prostate cancer cells

Project description:Genome-wide CRISPR screen was performed in LNCaP cells.

2017-09-28 | GSE72843 | GEO

A kinome-wide CRISPR screen identifies CK1α as a novel target to overcome enzalutamide resistance of prostate cancer

Project description:Utilizing a kinome-wide CRISPR-Cas9 knockout screen, we identified casein kinase 1 alpha (CK1α) as a novel therapeutic target to overcome enzalutamide resistance. To dissect the underlying mechanisms of targeting CK1α to sensitize cancer cells to ENZA, we performed RNA sequencing of 22Rv1 cells upon CK1α knockout or overexpression. We found that CK1α regulated double-strand break (DSB)-response signaling.

2023-03-10 | GSE203362 | GEO

Expression data from LNCaP cells treated with DHT and enzalutamide

Project description:Enzalutamide (formerly MDV3100 and available commercially as Xtandi), a novel androgen receptor (AR) signaling inhibitor, blocks the growth of castration-resistant prostate cancer (CRPC) in cellular model systems and was shown in a clinical study to increase survival in patients with metastatic CRPC. Enzalutamide inhibits multiple steps of AR signaling: (1) binding of androgens to AR, (2) AR nuclear translocation, and (3) association of AR with DNA. Here we used Affymetrix human genome microarray technology to investigate the global programme of gene expression of LNCaP cells in response to enzalutamide alone and in the context of DHT-stimulated androgen receptor gene expression. LNCaP cells were grown in RPMI 1640 supplemented with 5% hormone depleted FBS and treated with vehicle (control sample) , DHT (100 nM), enzalutamide (1 or 10 M-BM-5M) or DHT (100 nM) plus enzalutamide (1 or 10 M-BM-5M)for 16 hours for RNA extraction and hybridization. Each condition was done in triplicate.

2013-04-01 | E-GEOD-44905 | biostudies-arrayexpress

CRISPR-Cas9 RBM10 synthetic lethality screen

Project description:Genome-wide CRISPR-Cas9 knockout screen using TKOv1 sgRNA library was performed in isogenic RBM10-proficient and RBM10-deficient HCC827 cells.

2023-03-04 | E-MTAB-12724 | biostudies-arrayexpress

RNA-Sequencing Analysis of LNCaP Wildtype (WT) and RB-p53 CRISPR-Cas9 Double Knockout (DKO) Cells Treated with Enzalutamide

Project description:RNA-Sequencing Analysis of LNCaP Wildtype (WT) and RB-p53 CRISPR-Cas9 Double Knockout (DKO) Cells Treated with Enzalutamide

| PRJNA942354 | ENA

CRISPR screen

Project description:CRISPR screen

| OEX00023089 | NODE

RNA sequencing of LNCaP cells treated with castration and/or enzalutamide

Project description:The goal of this study was to determine how androgen receptor inhibition alters transcriptional programs in prostate cancer cells. LNCaP prostate cancer cells were grown in 10% charcoal-stripped serum (CSS) supplemented with 0.5 nanomolar dihydrotestosterone (DHT), in CSS without DHT modeling castration, with CSS + DHT but in the presence of 10 micromolar enzalutamide, or in CSS without DHT (castrated) and in the presence of enzalutamide for 72 hours. Analysis shows that androgen receptor target genes are reduced with castration, enzalutamide or the combination of castration + enzalutamide.

2022-05-12 | GSE202755 | GEO

CRISPR knockout screen implicates three genes in lysosome function

Project description:CRISPR knockout screen implicates three genes in lysosome function

| PRJNA530740 | ENA